Skip to Content
 
 
 
 

BVD-523-ABC: A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations (BVD-523-ABC)

Principal Investigator(s)
Heidi McKean, MD

Clinical Trial Categories

  • Genetics Studies
Contact
Medical Oncology Research Coordinators at 605-322-3295
or medoncresearch@avera.org
How to Participate

Clinical Trial Details >>

Location

  • Avera Cancer Institute at Sioux Falls
    1000 E. 23rd Street
    Sioux Falls, SD 57105
    Main: 605-322-3000
    Alternate: 800-657-4377

Moving Health Forward

Avera is a health ministry rooted in the Gospel. Our mission is to make a positive impact in the lives and health of persons and communities by providing quality services guided by Christian values.

© 2022 Avera Health, Sioux Falls, SD. All Rights Reserved.